RxDoctor Payments Data

Mohammed Siddiqui, DO

Pulmonary Disease · Naperville, ILNPI 1922361773

Payments from drug & device makers

$8,212in general payments, 2019–2025

Across 29 payments — averaging $283.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Boehringer Ingelheim$183
  • Actelion Pharmaceuticals US, Inc.$117
  • Johnson & Johnson$80
  • GSK$52
  • Dexcom, Inc.$40
  • plus $91 from 4 others

What the payments were for

  • Travel & lodging$6498%
  • Food & beverage$5637%
  • Education$7,00085%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,212 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$207,053
Medicare patients
438
Services billed
3,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$128,604
Breo ElliptaFluticasone/Vilanterol72$38,426
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr57$28,824
Incruse ElliptaUmeclidinium Bromide37$19,848
Spiriva RespimatTiotropium Bromide29$18,761
Stiolto RespimatTiotropium Br/Olodaterol Hcl33$15,991
DuleraMometasone/Formoterol11$6,113
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$5,938
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,385
Arnuity ElliptaFluticasone Furoate15$4,776
Tiotropium Bromide15$3,918
Albuterol Sulfate HfaAlbuterol Sulfate108$2,873
Ventolin HfaAlbuterol Sulfate22$1,737
Montelukast Sodium26$193
Fluticasone Propionate15$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$52$220,478345 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$183$34,75262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →